Portfolio company
Kindling Bio
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops a gene therapy platform that engineers tumour cells to display markers for the immune system to treat children with solid tumours.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
KiraGen Bio
This biotechnology company develops gene-edited cell therapies to treat solid tumours for patients with glioblastoma and other cancers.
Waypoint Bio
This company develops cell therapies for solid tumours using a spatial biology and machine learning platform to assist patients with difficult-to-treat cancers.
Siren Bio
This company develops immuno-gene therapies combining viral gene delivery and cytokine immunotherapy to treat solid tumours for cancer patients.
OverT Bio
This company develops engineered cell therapies and genetic screening platforms to treat patients with solid tumour cancers.
KiraGen
KiraGen develops multiplex gene-edited CAR-T cell therapies and an AI-driven drug discovery platform for patients with hard-to-treat solid tumours and glioblastoma.
Captain T Cell
The company develops cell therapies for cancer patients to treat solid tumours.
Neobe
The company develops engineered microbial biotherapeutics designed to disrupt the microenvironment of solid tumours for cancer patients receiving immunotherapy.
Akamis Bio
This clinical-stage oncology company develops intravenously administered immunotherapies to treat solid tumours, specifically targeting patients living with colorectal cancer.